Akeso and Summit reported overall survival results showing their PD-1/VEGF bispecific ivonescimab plus chemotherapy reduced the risk of death by 34% versus PD-1 inhibitor plus chemo in previously untreated, advanced squamous non-small cell lung cancer. The data come from the Phase 3 Harmoni-6 trial conducted entirely in China and were presented for the first time in the ASCO plenary session using a China-only dataset. Investigators reported a p-value of 0.0017, meeting a prespecified significance boundary of 0.0049 in the interim analysis. Oncologists described the magnitude as exceeding typical expectations for first-line OS outcomes in VEGF-inhibitor-based regimens. In earlier Harmoni studies, ivonescimab had shown progression-free survival advantages; the new overall survival data address lingering questions about whether VEGF-targeted strategies could translate into definitive OS improvement in first-line settings.